TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9551030
Drug: Warfarin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prescription for elderly females by general practitioners
Study: 9551030
Drug: Warfarin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prescription for elderly males by specialists
Study: 9551030
Drug: Warfarin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prescription for elderly males by general practitioners
Study: 1782954
Drug: Warfarin withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin withdrawal (sudden or gradual)
Study: 1782954
Drug: Warfarin withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin withdrawal
Study: 6784849
Drug: Radical mastectomy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical mastectomy followed by adjuvant chemotherapy (CMF: cyclophosphamide, methotrexate, fluorouracil)
Study: 30791944
Drug: Oxytocin-enhanced motivational
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin-enhanced motivational interviewing group therapy (MIGT)
Study: 30791944
Drug: Placebo-enhanced motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-enhanced motivational interviewing group therapy (MIGT)
Study: 26024940
Drug: Oral Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tranexamic Acid (TA)
Study: 24418284
Drug: Low-dose dynamic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dynamic CT with iterative reconstruction (ASIR) at 100 kV, 40% ASIR, 480 mg I/kg contrast
Study: 24418284
Drug: Conventional dynamic
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dynamic CT without ASIR at 120 kV, 0% ASIR, 600 mg I/kg contrast
Study: 10505156
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin 100 mg/m2, bleomycin 15 U/m2, and 5-fluorouracil 1000 mg/m2/day for 1-3 cycles followed by radiotherapy.
Study: 10505156
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with methotrexate 50 mg/m2 (1-6 weekly injections) followed by radiotherapy.
Study: 10505156
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin, bleomycin, and 5-fluorouracil followed by radiotherapy.
Study: 8867255
Drug: Mildly noxious
Normalized name: SIMPLYTHICK GEL ORAL MILDLY THICK 6GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mildly noxious constant current transdermal electrical stimulation
Study: 1533167
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia (TEA) with 0.375% bupivacaine plus sufentanil, 1:200,000 (5 micrograms/mL) and intraoperative GA with midazolam/N2O
Study: 4083810
Drug: Traditional method
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional method of preoperative skin preparation (routine shaving with cetrimide and chlorhexidine in alcohol)
Study: 23661044
Drug: Topical MMC
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical MMC (0.2 mg/mL for 3 min)
Study: 17228349
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol margarine (2 g of plant sterols daily)
Study: 17228349
Drug: Stanol-enriched margarine
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanol-enriched margarine (2 g of stanols daily)
Study: 3003715
Drug: Rhesus rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus rotavirus vaccine (RRV) MMU 18006, 10^5 plaque-forming units
Study: 27607861
Drug: Oxytocin challenge
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin challenge test (5 international units/500 mL oxytocin Ringer lactate infused at a rate of 12 mL/h, doubled every 10 minutes until three uterine contractions per 10‐minute interval)
Study: 26652987
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg perindopril arginine salt
Study: 26652987
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg perindopril tert-butylamine salt
Study: 23440570
Drug: darunavir/ritonavir (DRV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir (DRV/r) 800/100 mg
Study: 23440570
Drug: lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir (LPV/r) 800/200 mg
Study: 17699280
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor plus candesartan (2 to 12 mg/d)
Study: 10624998
Drug: Remifentanil 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0 ng/mL
Study: 10624998
Drug: Remifentanil 2
Normalized name: remifentanil 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 2 ng/mL
Study: 10624998
Drug: Remifentanil 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 4 ng/mL
Study: 10624998
Drug: Remifentanil 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 8 ng/mL
Study: 10624998
Drug: Remifentanil 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 16 ng/mL
Study: 1389512
Drug: High-dose prochlorperazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prochlorperazine 0.8 mg/kg intravenously
Study: 1389512
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide 2 mg/kg intravenously
Study: 27383293
Drug: 0.5 g/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg/week IVIG
Study: 27383293
Drug: 1.0 g/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/kg/week IVIG
Study: 23252878
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg vortioxetine
Study: 15472494
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg (titrated to 10 mg after 4 weeks)
Study: 15472494
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 mg (titrated to 5 mg and 10 mg after 1 and 3 weeks)
Study: 3526534
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) monotherapy without steroids
Study: 29415846
Drug: Opioid-dependence pharmacotherapy
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-dependence pharmacotherapy (methadone, buprenorphine, oral naltrexone)
Study: 29415846
Drug: Opioid-dependence pharmacotherapy
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-dependence pharmacotherapy group
Study: 29415846
Drug: Outpatient substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient substance abuse treatment without opioid-dependence pharmacotherapy
Study: 24571282
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text messages for 6 months
Study: 21110437
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 250-1000 mg ademetionine for 28 days
Study: 21110437
Drug: Yinzhihuang Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yinzhihuang Granule and Compound Glycyrrhizin Injection (control group)
Study: 12814852
Drug: venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: venlafaxine XR (75 or 150 mg/d)
Study: 12814852
Drug: diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (15 mg/d)
Study: 12814852
Drug: venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: venlafaxine XR (75 or 150 mg/d) from verum-sensitive centres
Study: 1653140
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg sumatriptan (second dose at 1 hour)
Study: 1653140
Drug: placebo (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (second dose at 1 hour)
Study: 6411497
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 25 mg/day
Study: 6411497
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 50 mg/day
Study: 6411497
Drug: Mesterolone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesterolone (100 mg/day)
Study: 6411497
Drug: Testosterone rebound
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone rebound therapy (100 or 250 mg on alternate weeks)
Study: 9386141
Drug: Maxepa 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxepa 5 capsules BID for 3 months
Study: 3219274
Drug: Prednisolone 5
Normalized name: prednisolone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 5 mg bd
Study: 3219274
Drug: Primary endocrine
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary endocrine treatment alone (PET)
Study: 23234810
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate 20 mg/d (early-treatment)
Study: 23234810
Drug: Placebo (delayed-treatment)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (delayed-treatment)
Study: 15333721
Drug: DHA-enriched baby
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-enriched baby food (115 mg DHA/100 g food, 1 jar (113 g)/d)
Study: 15333721
Drug: Control baby
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control baby food (0 mg DHA)
Study: 8083711
Drug: Split hyperfractionated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split hyperfractionated radiotherapy (2.0 Gy/d for 30 to 40 days, total 48 Gy to 60 Gy) and chemotherapy (cisplatin 80 to 100 mg/m2 and fluorouracil 1,000 mg/m2 for 3 to 4 days, +/- vindesine 8 mg/m2 for two cycles)
Study: 8083711
Drug: Split hyperfractionated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split hyperfractionated radiotherapy and chemotherapy
Study: 2809258
Drug: Purified acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified acellular pertussis vaccine (12.5 micrograms LPF and 12.5 micrograms FHA)
Study: 1108565
Drug: Heparin 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5,000 i.u. every 12 hours
Study: 31661012
Drug: Biological dressing
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological dressing composed of fetal fibroblasts and keratinocytes
Study: 22123381
Drug: Levocetirizine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine, 5 mg daily for 1 week
Study: 22123381
Drug: Cetirizine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, 10 mg daily for 1 week
Study: 22123381
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill for 1 week
Study: 16691131
Drug: ICP-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-directed therapy in patients with severe TBI (n = 24)
Study: 15285121
Drug: Different descriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different descriptions of winning conditions (e.g., 'if one or the other but not both picks a red card' vs. 'if one or the other but not both picks a black card')
Study: 8276048
Drug: Ramipril 1.25
Normalized name: ramipril 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 1.25 mg
Study: 3440636
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ketanserin and hydrochlorothiazide
Study: 25064437
Drug: Peginterferon lambda-1a
Normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon lambda-1a (Lambda) 120/180/240 μg
Study: 25064437
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a (alfa) 180 μg
Study: 18762591
Drug: Family-focused treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused treatment for adolescents (FFT-A) and protocol pharmacotherapy (n = 30)
Study: 18762591
Drug: Enhanced care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced care (EC) and protocol pharmacotherapy (n = 28)
Study: 31518717
Drug: Magnetic Sphincter
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic Sphincter Augmentation (MSA)
Study: 31263057
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (325 mg/day)
Study: 21610123
Drug: diacerein (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: diacerein (50 mg once daily for the first 15 days and twice daily for 45 additional days)
Study: 19492999
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of green tea
Study: 19492999
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of white tea
Study: 16541308
Drug: Sentinel lymph
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sentinel lymph node biopsy (SLNB) using a combination of radiopharmaceutical 99mTc‐albumin colloid and Patent Blue V dye
Study: 16541308
Drug: Sentinel lymph
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sentinel lymph node biopsy (SLNB) using a combination of blue dye and isotope
Study: 21838089
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel microsphere 0.1%
Study: 1644335
Drug: 4-aminosalicylic acid
Normalized name: 4-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-aminosalicylic acid (4-ASA) 2 g enemas
Study: 1644335
Drug: Prednisolone 20
Normalized name: prednisolone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 20 mg enemas
Study: 6092557
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (40 patients)
Study: 6092557
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment with bronchodilators
Study: 6092557
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (with or without bronchodilators)
Study: 29288501
Drug: Iodine supplementation
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine supplementation (10 grams of iodized salt daily)
Study: 24385534
Drug: Deferasirox (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (target dose 40 mg/kg per day)
Study: 24385534
Drug: Deferoxamine (50‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine (50‐60 mg/kg per day for 5‐7 days/week)
Study: 20456627
Drug: female arousal
Approvals — FDA: no, EMA: no, PMDA: no
Description: female arousal gel
Study: 16336447
Drug: 0.09 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.09 mg/kg midazolam
Study: 12201618
Drug: Mix25 (25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mix25 (25% insulin lispro and 75% NPL)
Study: 30293464
Drug: Internally cooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internally cooled wet (ICW) electrodes with saline infusion
Study: 29753033
Drug: Nemolizumab 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab 0.1 mg/kg Q4W
Study: 29753033
Drug: Nemolizumab 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab 0.5 mg/kg Q4W
Study: 29753033
Drug: Nemolizumab 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab 2.0 mg/kg Q4W
Study: 29753033
Drug: Nemolizumab 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab 2.0 mg/kg Q8W
Study: 19961017
Drug: TIVA (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA (total intravenous anesthesia)
Study: 17980419
Drug: Fish Oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish Oil (FO) supplementation with 0.5 g of docosahexaenoic acid and 0.15 g of eicosapentaenoic acid, 400 mug of methyl‐tetra‐hydrofolic acid
Study: 31929122
Drug: Gocovri (amantadine)
Normalized name: Gocovri
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gocovri (amantadine) 274 mg once daily at bedtime
Study: 31778629
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (1.5 g every 6 hours)
Study: 29052559
Drug: Niaoduqing particles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaoduqing particles 5 g thrice daily and 10 g before bedtime for 24 weeks
Study: 29052559
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered using the same methods for 24 weeks
Study: 26174334
Drug: Psychoeducation (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation (6 weekly sessions)
Study: 26174334
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise (6 weekly sessions)
Study: 19137409
Drug: Bicarbonate (Bi)
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate (Bi) infusion in dextrose water
Study: 19137409
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide (AZ) with normal saline (NLS)
Study: 19137409
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NLS) infusion alone
Study: 17507633
Drug: Adjuvant taxane-anthracycline-containing
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant taxane-anthracycline-containing chemotherapy and/or trastuzumab (Herceptin)
Study: 9595988
Drug: OPC-14117 60
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-14117 60 mg/d
Study: 9595988
Drug: OPC-14117 120
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-14117 120 mg/d
Study: 9595988
Drug: OPC-14117 240
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-14117 240 mg/d
Study: 2539017
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 to 40 mg daily)
Study: 2539017
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 to 100 mg daily)
Study: 23537617
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (goserelin) for 3 months (Group 1)
Study: 19691907
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg quetiapine XR
Study: 19691907
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg quetiapine XR
Study: 18624596
Drug: Medication, reducing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication, reducing salty foods, and losing weight
Study: 15780844
Drug: D-serine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-serine (30 mg/kg/day)
Study: 11870242
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid (0.25 mg, 0.5 mg, 1 mg at three-month intervals; 4 mg as a single dose; 2 mg doses six months apart)
Study: 10195357
Drug: Cetirizine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (20 mg)
Study: 10195357
Drug: Dimethindene (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethindene (4 mg)
Study: 10195357
Drug: H1-antagonists (Cetirizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1-antagonists (Cetirizine and Dimethindene)
Study: 7850984
Drug: 0.8 mg/h
Normalized name: nitroglycerin 0.8 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg/h transdermal nitroglycerin
Study: 1691125
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy only
Study: 1691125
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy followed by endoscopic intubation
Study: 7361087
Drug: Diflunisal (500-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (500-750 mg daily)
Study: 7361087
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (2000-3000 mg daily)
Study: 25481453
Drug: 4-week taper
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week taper condition (N=22)
Study: 17239942
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml Patent Blue diluted with 8 ml NaCl 0.9%
Study: 17239942
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml Patent Blue (standard labelling volume)
Study: 9714946
Drug: Danger ideation
Normalized name: After banger
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Danger ideation reduction therapy (DIRT)
Study: 7992096
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy (CVD) plus interleukin-2 (IL-2) and interferon-alfa (IFN-alpha)
Study: 7992096
Drug: Biotherapy (IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotherapy (IL-2 plus IFN-alpha) administered immediately after CVD
Study: 7992096
Drug: Biotherapy (IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotherapy (IL-2 plus IFN-alpha) administered in a sandwich of biotherapy/CVD/biotherapy